Recent Transactions

11-May-17
$245 million
Saudi Arabia
Target: 

Equity stake in Bupa Arabia

uk.gif
Acquiror: 
Bupa Ltd.

Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia

10-Jan-17
$204 million
U.S.A. flag
Target: 

Derma Sciences, Inc.

U.S.A. flag
Acquiror: 
Integra LifeSciences Holdings Corporation

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology

09-Jan-17
$465 million
U.S.A. flag
Target: 

Palatin Technologies, Inc. lead product candidate, Rekynda

U.S.A. flag
Acquiror: 
AMAG Pharmaceuticals, Inc.

Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.

24-Nov-16
$NA
israel.gif
Target: 

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

switzerland.gif
Acquiror: 
Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

23-Nov-16
$NA
israel.gif
Target: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

france.gif
Acquiror: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

13-Oct-16
$NA
usa_canada.gif
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

05-Oct-16
$775 million
uk-ireland_35558.gif
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

india.gif
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

05-Oct-16
Pending
$NA
israel.gif
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

india.gif
Acquiror: 
Accord Healthcare Ltd.

Advising Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

04-Oct-16
$223 million
usa_uk.gif
Target: 

U.S. rights to Toprol-XL (AstraZeneca)

canada.gif
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the U.S. rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

09-Aug-16
$NA
australia.gif
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

28-Jul-16
$80 million
U.S.A. flag
Target: 

BioD, LLC

U.S.A. flag
Acquiror: 
Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

28-Jun-16
$NA
israel.gif
Target: 

U.S. rights to an authorized generic version of Adderall XR

U.S.A. flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to an authorized generic version of Adderall XR

28-Jun-16
$652 million
israel.gif
Target: 

U.S. rights to 37 approved and 5 pipeline generic products

australia.gif
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to 42 generic products

21-Jun-16
$586 million
israel.gif
Target: 

U.S. rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

U.S.A. flag
Acquiror: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

20-Jun-16
$NA
israel.gif
Target: 

U.S. rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

india.gif
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 2 generic drug products to Zydus Cadila

16-Jun-16
$40 million
israel.gif
Target: 

U.S. rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

U.S.A. flag
Acquiror: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

15-Jun-16
$414 million
U.S.A. flag
Target: 

Aegerion Pharmaceuticals

canada.gif
Acquiror: 
QLT Inc.

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

11-Jun-16
$350 million
israel.gif
Target: 

U.S. rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

india.gif
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 8 generic drug products to Dr. Reddy’s Laboratories

04-May-16
$NA
U.S.A. flag
Target: 

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

U.S.A. flag
Acquiror: 
Ligand Pharmaceuticals

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

19-Apr-16
$NA
U.S.A. flag
Target: 

Total Care Medicaid Plan

U.S.A. flag
Acquiror: 
Molina Healthcare, Inc.

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

07-Mar-16
$NA
germany.gif
Target: 

Boehringer Ingelheim

U.S.A. flag
Acquiror: 
AbbVie

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

01-Dec-15
$NA
uk.gif
Target: 

Allied Healthcare

germany.gif
Acquiror: 
AURELIUS Investments

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

29-Oct-15
$275 million
U.S.A. flag
Target: 

Aesynt, Inc.

U.S.A. flag
Acquiror: 
Omnicell, Inc.

Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems

27-Jul-15
$40.5 billion
ireland.gif
Target: 

Allergan Generics

israel.gif
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

06-Jul-15
$910 million
U.S.A. flag
Target: 

Altegra Health, Inc.

U.S.A. flag
Acquiror: 
Emdeon Inc.

Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare

Pages

show all